Literature DB >> 28871564

Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.

Arsen Osipov1, Nicholas Nissen2, Joanne Rutgers3, Deepti Dhall3, Jason Naziri4, Shefali Chopra3, Quanlin Li1, Andrew Eugene Hendifar1, Richard Tuli5.   

Abstract

PURPOSE: There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA.
METHODS: We identified 105 patients with resected PDA. Pancreatic, anterior, bile duct, and posterior surgical resection margins (PM; posterior surface, uncinate and vascular groove) were identified. Three pathologists reviewed all archival surgical specimens and recategorized each margin as tumor at ink/transected, <0.5, 0.5-1, >1-2, or >2 mm from the inked surface. The impact of these and other clinical variables was assessed on local control, disease-free survival (DFS), and overall survival (OS).
RESULTS: Among all margins, PM clearance up to 2 mm was prognostic of DFS (p = 0.01) and OS (p = 0.01). Dichotomizing the PM at 2 mm revealed it to be an independent predictor of local recurrence-free survival [hazard ratio HR] 0.20, 95% confidence interval [CI] 0.048-0.881, p = 0.033), DFS (HR 0.46, 95% CI 0.22-0.96, p = 0.03), and OS (HR 0.31, 95% CI 0.14-0.74, p = 0.008). A margin status of >2 mm was also prognostic of OS in patients who received adjuvant chemotherapy (HR 0.31, 95% CI 0.11-0.89, p = 0.03), however this difference was mitigated in patients receiving adjuvant chemoradiotherapy (HR 0.40, 95% CI 0.10-1.58, p = 0.19).
CONCLUSION: These data highlight the clinical significance of the PM and the lack of significance of other resection margins. Clearance in excess of 2 mm should be considered to improve long-term clinical outcomes. The use of adjuvant radiotherapy should be strongly considered in patients with PMs <2 mm.

Entities:  

Mesh:

Year:  2017        PMID: 28871564     DOI: 10.1245/s10434-017-6076-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.

Authors:  Asmita Chopra; Mazen Zenati; Melissa E Hogg; Herbert J Zeh; David L Bartlett; Nathan Bahary; Amer H Zureikat; Joal D Beane
Journal:  Ann Surg Oncol       Date:  2021-05-23       Impact factor: 5.344

2.  Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity.

Authors:  Ian R Munhenzva; Connor W Barth; Martha Sibrian-Vazquez; Lei G Wang; Jorge O Escobedo; Summer L Gibbs; Robert M Strongin
Journal:  Methods       Date:  2019-06-08       Impact factor: 3.608

3.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

4.  Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.

Authors:  Steve Walston; Joseph Salloum; Carmine Grieco; Evan Wuthrick; Dayssy A Diaz; Christian Barney; Andrei Manilchuk; Carl Schmidt; Mary Dillhoff; Timothy M Pawlik; Terence M Williams
Journal:  Am J Clin Oncol       Date:  2018-12       Impact factor: 2.339

5.  Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy.

Authors:  Caitlin A McIntyre; Constantinos P Zambirinis; Alessandra Pulvirenti; Joanne F Chou; Mithat Gonen; Vinod P Balachandran; T Peter Kingham; Michael I D'Angelica; Murray F Brennan; Jeffrey A Drebin; William R Jarnagin; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2020-05-25       Impact factor: 5.344

Review 6.  Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma.

Authors:  Aaron J Grossberg; Linda C Chu; Christopher R Deig; Eliot K Fishman; William L Hwang; Anirban Maitra; Daniel L Marks; Arnav Mehta; Nima Nabavizadeh; Diane M Simeone; Colin D Weekes; Charles R Thomas
Journal:  CA Cancer J Clin       Date:  2020-07-19       Impact factor: 508.702

7.  Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cross-specialty Survey From the Pancreatobiliary Pathology Society Grossing Working Group.

Authors:  Deepti Dhall; Jiaqi Shi; Daniela S Allende; Kee-Taek Jang; Olca Basturk; Volkan Adsay; Grace E Kim
Journal:  Am J Surg Pathol       Date:  2021-10-01       Impact factor: 6.298

8.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2019-06       Impact factor: 13.787

Review 9.  Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?

Authors:  Elisabetta Fenocchio; Roberto Filippi; Pasquale Lombardi; Virginia Quarà; Michela Milanesio; Giacomo Aimar; Francesco Leone; Massimo Aglietta
Journal:  Cancers (Basel)       Date:  2019-10-12       Impact factor: 6.639

10.  Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma.

Authors:  Eddie Zhang; Lora Wang; Talha Shaikh; Elizabeth Handorf; J Karen Wong; John P Hoffman; Sanjay Reddy; Harry S Cooper; Steven J Cohen; Efrat Dotan; Joshua E Meyer
Journal:  Ann Surg Oncol       Date:  2021-06-10       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.